These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6362907)

  • 41. [Intracoronary thrombolysis in acute myocardial infarction].
    Kanmatsuse K; Kajiwara N
    J Cardiogr Suppl; 1984; (3):69-80. PubMed ID: 6536693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)].
    Gulba DC; Bode C; Topp J; Höpp HW; Westhoff-Bleck M; Rafflenbeul W; Lichtlen PR
    Z Kardiol; 1990 Apr; 79(4):279-85. PubMed ID: 2113330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of intravenous infusion of urokinase on coronary artery thrombolysis in the dog.
    Isojima K; Sato Y; Lew A; Ganz W
    Jpn Circ J; 1985 Nov; 49(11):1195-200. PubMed ID: 4094039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.
    Tiefenbrunn AJ; Robinson AK; Kurnik PB; Ludbrook PA; Sobel BE
    Circulation; 1985 Jan; 71(1):110-6. PubMed ID: 4038368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
    Van de Werf F; Nobuhara M; Collen D
    Ann Intern Med; 1986 Mar; 104(3):345-8. PubMed ID: 3080936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
    Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
    Gu S; Ducas J; Patton JN; Greenberg D; Prewitt RM
    Chest; 1992 Jun; 101(6):1684-90. PubMed ID: 1600792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies.
    Mitchel JF; Fram DB; Palme DF; Foster R; Hirst JA; Azrin MA; Bow LM; Eldin AM; Waters DD; McKay RG
    Circulation; 1995 Feb; 91(3):785-93. PubMed ID: 7828307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein thrombosis model.
    Matsuo O; Bando H; Okada K; Tanaka K; Tsukada M; Iga Y; Arimura H
    Thromb Res; 1986 Apr; 42(2):187-94. PubMed ID: 3087008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ; Hanson M; FitzGerald GA
    J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion.
    Topol EJ; Ciuffo AA; Pearson TA; Dillman J; Builder S; Grossbard E; Weisfeldt ML; Bulkley BH
    J Am Coll Cardiol; 1985 Jan; 5(1):85-91. PubMed ID: 4038373
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
    Jang IK; Gold HK; Ziskind AA; Fallon JT; Holt RE; Leinbach RC; May JW; Collen D
    Circulation; 1989 Apr; 79(4):920-8. PubMed ID: 2494006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous administration of recombinant tissue plasminogen activator. Optimizing the rate of coronary thrombolysis.
    Prewitt RM; Gu S; Schick U; Ducas J
    Chest; 1995 Apr; 107(4):1146-51. PubMed ID: 7705128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergism of thrombolytic agents in vivo.
    Collen D; Stassen JM; Stump DC; Verstraete M
    Circulation; 1986 Oct; 74(4):838-42. PubMed ID: 3093116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life.
    Weinheimer CJ; James HL; Kalyan NK; Wilhelm J; Lee SG; Hung PP; Sobel BE; Bergmann SR
    Circulation; 1991 Apr; 83(4):1429-36. PubMed ID: 1901531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.